PubMed Health⌕ Search

Biomedical subjects

A Strano

Publications and source records attributed to A Strano.

At least 91 records · Page 5Linked to original sources
PubMed1986

Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.

Ketanserin is a new strong antiserotoninergic drug that, unlike the previous ones, is selective for 5-hydroxytryptamine receptors. This drug has been employed successfully in the treatment of arterial hypertension and of some peripheral vascular diseases. The authors are carrying out a trial on medium term treatment with ketanserin (K) or propranolol (P) in comparison with placebo, to evaluate their effects on blood pressure, haemocoagulative parameters and peripheral circulation. The trial is a double-blind cross-over random trial on subjects with mild or moderate hypertension. Until now 13 patients have ended the study; six of them are suffering from arteriosclerosis obliterans of the lower limbs at 1st or 2nd stage according to Fontaine. Both propranolol and ketanserin significantly reduced the blood pressure, although the decrease in systolic blood pressure was more evident after propranolol. Heart rate diminished significantly only after propranolol administration. The noninvasive, intermittent (every 30 min) monitoring of blood pressure showed a significant 24-hour reduction of blood pressure after administration of propranolol or ketanserin without significant changes of circadian behaviour of the blood pressure. After administration of ketanserin a slight improvement in peripheral circulation was demonstrated, evaluated by using strain-gauge plethysmography. As regards the results obtained for platelet function and other haemocoagulative parameters examined, adenosine diphosphate-induced platelet aggregation, adenosine diphosphate slope, collagen lag period, antithrombin III biological activity, and serum fibrinogen did not show noticeable modifications after treatment, while beta-thromboglobulin levels decreased slightly after ketanserin administration.

Adult↗
PubMed1986

Enhanced platelet sensitivity to prostacyclin after isosorbide-5-mononitrate in patients with stable angina pectoris.

Recently the possibility that nitrates inhibit platelet function in man has been explored in vitro and in vivo. We have studied the effect of isosorbide-5-mononitrate (ISMN), a stable and long-acting organic nitrate, on platelet function in vivo. Given orally within the current therapeutic range, the drug has practically no effect on platelet aggregation nor thromboxane generation in platelet-rich plasma in response to ADP, collagen, arachidonate, epinephrine and PAF. Synergistic effects of prostacyclin and ISMN on inhibition of ADP-induced platelet aggregation have been observed. Thus, local inhibition of platelet aggregation might not have been detectable, due to the short half-life in vitro of prostacyclin.

Adult↗
PubMed1985

Platelet thromboxane production in liver cirrhosis.

To determine whether platelet prostaglandin production in patients with liver cirrhosis was as impaired as platelet aggregation, serum thromboxane production was studied in 52 patients with liver cirrhosis; 12 patients had consumed more than 80 gr of alcohol/day, for more than ten years; 13 patients had also had diabetes mellitus for more than two years. A reduced thromboxane synthesis by platelets of liver disease patients was observed; the parallel decrease of both platelet thromboxane and serum PGE2 formation may also suggest a decrease in arachidonic acid availability for prostaglandin and thromboxane production. A smaller reduction of thromboxane and PGE2 formation in cirrhotics with diabetes mellitus or chronic alcohol intake was also observed.

Adult↗
PubMed1985

Ambulatory BP monitoring after acute administration of slow release nifedipine, alone or in combination with acebutolol, in systo-diastolic and in systolic hypertension.

Ambulatory monitoring of BP was performed in 11 patients whose 6 suffering from systo-diastolic (group 1) and 5 from systolic hypertension only (group 2) by Pressurometer III Del Mar Avionics after placebo (P), slow release Nifedipine (srN) 20 mg b.d. and srN plus Acebutolol (A) 400 mg in the morning, administered in 3 different days according to a randomized scheme. In both group we observed a significant decrease of BP after srN during 24 hrs, but in pts. of the group 2 the reduction of systolic BP was prevalent. After administration of srN+A the decrease of BP was more consistent in both groups of pts. HR showed a reflex increase in both groups of pts. after srN, antagonized by A, especially in pts. of group 2. Variability of BP considered as difference between the min and max levels of BP during 24 hrs decreased significantly with both treatments, while variability calculated as mean of the standard deviations and as coefficient of variability did not show significant changes in both groups of pts.

Acebutolol↗
PubMed1985

Calf blood flow and vascular resistance in middle-aged and elderly hypertensives.

Hypertension is associated with increased total peripheral vascular resistance. Calf blood flow and vascular resistance in two groups of hypertensives of different age has been evaluated: 85 middle-aged hypertensives (MH) and 25 elderly hypertensives (EH), and in two groups of 20 normotensive control subjects of similar age. Calf blood flow at rest (RF) and after ischaemia (PF) was determined by strain-gauge plethysmography. Basal (BVR) and minimal (MVR) vascular resistance were obtained by the mean blood pressure (MBP):RF and MBP:PF ratio. Blood flow at rest was reduced only in EH, while PF was significantly lower in MH and in EH in comparison with the respective controls. In parallel, BVR and MVR were higher in MH and in EH compared with controls. The increase of BVR and of MVR was more evident in EH. These results suggest that in EH there is an impairment of the calf maximal vasodilatation capacity, probably due to the long duration of hypertension.

Adolescent↗